The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously ...

ONCOLife is delighted to announce that Dr İlkiz Er Dağ, MD, MBA, has joined the company as Project Director for Oncology ...

New 10-year results from the APHINITY trial show that adding pertuzumab (Perjeta®) to trastuzumab (Herceptin®) and ...

The V Foundation for Cancer Research, a top-rated cancer charity, announced an exciting partnership with Cancer Vaccine ...